Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Neoadjuvant Pyrotinib Quadruplet Significantly Improves pCR in HER2+ Breast Cancer

June 6th 2021

The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

Neoadjuvant Pertuzumab Plus Trastuzumab/Nab-Paclitaxel Achieves 64% pCR With Less Toxicity in HER2+ Breast Cancer

June 6th 2021

Pertuzumab plus trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer induced a pathologic complete response similar to that achieved with docetaxel, carboplatin, trastuzumab, and pertuzumab, with less treatment-related toxicities.

Meaningful Impact on Outcomes Demonstrated with De-Escalation Strategy in HER2+/HR– Breast Cancer

June 6th 2021

A de-escalated course of neoadjuvant therapy of trastuzumab and pertuzumab with or without added weekly paclitaxel for only 12 weeks yielded high response rates and significant survival in patients with HER2-positive, hormone receptor–negative early breast cancer.

Durvalumab Plus Neoadjuvant Chemotherapy Yields Long-Lasting Survival in Early TNBC

June 6th 2021

The addition of durvalumab to neoadjuvant anthracycline and taxane–based chemotherapy was found to significantly improve survival in patients with early triple-negative breast cancer.

Ribociclib/Fulvestrant Maintains Survival Benefit in Postmenopausal HR+ Advanced Breast Cancer, Irrespective of Setting

June 5th 2021

Ribociclib plus fulvestrant continued to significantly improve overall survival over fulvestrant alone in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up, irrespective of whether patients received the regimen in the first- or second-line setting.

Venetoclax/Fulvestrant Combo Found to Be Inferior to Fulvestrant Alone in ER+/HER2- Breast Cancer

June 5th 2021

The combination of venetoclax and fulvestrant failed to improve overall outcomes vs fulvestrant alone in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor.

Palbociclib/Fulvestrant Combo Maintains OS Benefit in HR+ Breast Cancer

June 5th 2021

At a median follow-up of 73.3 months, investigators in the PALOMA-3 trial have concluded that palbociclib plus fulvestrant maintains a clinically meaningful improvement in overall survival compared with placebo plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer

June 5th 2021

Dennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Tucatinib Plus Trastuzumab/Capecitabine Maintain Survival Benefit in HER2-Positive Breast Cancer

June 5th 2021

Tucatinib plus trastuzumab and capecitabine maintained and even improved overall survival over placebo in pretreated patients with HER2-positive breast cancer.

Tucatinib Concentrations in CSF Demonstrated in HER2+ Metastatic Breast Cancer

June 4th 2021

Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.

Olaparib Provides Meaningful Benefit 1 Year After Standard of Care Therapies in BRCA1/2+, High-Risk, Early HER2- Breast Cancer

June 3rd 2021

Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence.

Dr. Lower on the Importance of Tucatinib Plus Capecitabine/Trastuzumab in HER2+ Breast Cancer

June 2nd 2021

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Johnson Shines a Light on Racial Disparities in Breast Cancer, Prostate Cancer, and Beyond

June 2nd 2021

Anita Johnson, MD, FACS, discusses existing disparities in cancer, studies that have helped to shed further light on the issue, and ongoing efforts being made to improve outcomes in all patients.

FDA Grants Priority Review to Plinabulin Plus G-CSF for CIN Prevention

June 1st 2021

The FDA has granted a priority review to the new drug application seeking approval of plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Sutherland on the Promise of CDK4 Inhibitors in Metastatic Breast Cancer

May 27th 2021

Diana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.

Treatment of Advanced HER2-Positive Breast Cancer

May 27th 2021

Dr Jhaveri and colleagues highlight key clinical trials in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Treatment of Early-Stage HER2-Positive Breast Cancer

May 27th 2021

Dr Jhaveri and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Unmet Needs in the Treatment of HER2-Positive Breast Cancer

May 27th 2021

In the first segment, Dr Jhaveri and colleagues discuss the unmet needs clinicians face in the treatment of patients with HER2-positive breast cancer.

Treatment of Metastatic HER2-Positive Breast Cancer

May 26th 2021

Dr Kaklamani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer

May 26th 2021

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.